By Medha Singh and Shivani Kumaresan
(Reuters) – U.S. stock index futures rose on Friday as Pfizer said it could apply for emergency use of its COVID-19 vaccine candidate as early as November and as data showed stronger-than-expected retail sales growth last month.
The drugmaker’s shares (N:) firmed 2.1% in premarket trading as it expects to provide safety data and file for authorization of the vaccine, which it is developing with Germany’s BioNTech SE (F:), as soon as a safety milestone is achieved in the third week of November.
BioNTech’s U.S.-listed shares (O:) jumped 3.4%.
“The markets trade on hopes and promise, and the Pfizer news only aids that narrative even more,” said Jake Dollarhide, chief executive officer at Longbow Asset Management in Tulsa, Oklahoma.
Latest data showed U.S. retail sales increased more than expected in September, though the recovery from the recession is at a crossroads as government money runs out and new COVID-19 infections surge across the country.
Trading on Wall Street this week has been dictated by news about more federal aid to help businesses and households reeling from the impact of the COVID-19 pandemic, with the S&P 500 on track for its smallest weekly gains in three.
Talks between Democrats and Republicans also seem unlikely to yield a deal before the Nov. 3 election.
President Donald Trump and Democratic challenger Joe Biden will return to the campaign trail with visits to three battleground states, a day after the two contenders clashed from afar during dueling televised town halls.
Meanwhile, after a mixed start to the third-quarter earnings season from the big Wall Street lenders, investors will look next week to results from Netflix Inc (O:), one of the technology mega-caps that have benefited from stay-at-home demand during the pandemic.
Analysts’ expectations for S&P 500 companies’ earnings have improved to an 18.8% fall from a 25% tumble forecast three months earlier.
Schlumberger (N:) dropped 1% after the top oilfield services provider reported a third straight quarterly loss.
At 8:36 a.m. ET, were up 123 points, or 0.43%, S&P 500 e-minis
Boeing Co (N:) rose 4% as a report said Europe’s aviation regulator had declared the U.S. planemaker’s 737 MAX safe to fly again.
Gilead Sciences Inc (O:) slipped 0.9% as a World Health Organization study concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital. The company has questioned the findings of the study.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.